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profiles, potentially interacting pharmacotherapy, and related adverse events in second-generation an-
tipsychotics (SGAs) users of a tertiary care hospital. Within our pharmacoepidemiological database
derived from electronic medical records of 82,358 hospitalizations, we identified 1136 hospitalizations
contributing 9165 patient-days with exposure to SGA. Blood pressure, blood glucose, lipids, and BMI
had been documented in 97.7, 75.7, 24.6, and 77.4% of hospitalizations, respectively. Among these, the
prevalence of hypertension, hyperglycemia, dyslipidemia, and BMI 30 kg/m or more was 36.9, 22.6, 61.1,
and 23.1%, respectively. A total of 63.4, 70.8, and 37.1% of SGA users with hyperglycemia, dyslipi-
demia, and hypertension, respectively, received no pharmacotherapy for these conditions. We identified
614 patient-days with SGA plus formally contraindicated comedication and another 1066 patient-days
with other high-risk combinations for QTc prolongation. Among those there was one case with associated
neutropenia and four cases with abnormal QTc interval. However, specific monitoring for such adverse
events was not documented in 45.5% of hospitalizations with contraindicated and 89.8% with high-risk
QTc-prolonging combinations. Our study identified targets for improved monitoring and management
in SGA users. These may be implemented as automated alerts into electronic prescribing systems and
thereby efficiently support safer pharmacotherapy in clinical practice.
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ABSTRACT 
We conducted an observational study that analyzed population characteristics, metabolic 
profiles, potentially interacting pharmacotherapy and related adverse events in second-
generation antipsychotics (SGA) users of a tertiary care hospital. Within our 
pharmacoepidemiological database derived from electronic medical records of 82358 
hospitalizations we identified 1136 hospitalizations contributing 9165 patient-days with 
exposure to SGA. Blood pressure, blood glucose, lipids and body mass index had been 
documented in 97.7, 75.7, 24.6 and 77.4% of hospitalizations, respectively. Among those the 
prevalence of hypertension, hyperglycemia, dyslipidemia and BMI ≥30 kg/m² was 36.9, 22.6, 
61.1 and 23.1%, respectively. 63.4, 70.8 and 37.1% of SGA users with hyperglycemia, 
dyslipidemia and hypertension, respectively, had no pharmacotherapy for these conditions. 
We identified 614 patient-days with SGA plus formally contraindicated co-medication and 
another 1066 patient-days with other high-risk combinations for QTc prolongation. Among 
those there were one case with associated neutropenia and four with abnormal QTc-interval. 
However, specific monitoring for such adverse events was not documented in 45.5% of 
hospitalizations with contraindicated and 89.8% with high-risk QTc-prolonging 
combinations. 
Our study identified targets for improved monitoring and management in SGA users. These 
may be implemented as automated alerts into electronic prescribing systems and thereby 
efficiently support safer pharmacotherapy in clinical practice. 
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INTRODUCTION 
Second-generation antipsychotics (SGA) are primarily indicated for the treatment of 
schizophrenic disorders, and some SGA such as quetiapine, risperidone, aripiprazole and 
lurasidone also have labeled indications for other psychiatric disorders including bipolar 
diseases. A pronounced rise in the use of antipsychotics has been observed over the past 20 
years, which is mostly attributable to the increased prescription of SGA since their 
introduction in the mid 90's (Donohue et al., 2014; Verdoux et al., 2010). Off-label use has 
also been reported to be very common for SGA in clinical practice, e.g. for the treatment of 
dementia and symptoms of anxiety, sleep and neurotic disorders (Linden and Thiels, 2001; 
McKean and Monasterio, 2012). 
SGA are not generally more effective than first-generation antipsychotics (FGA) (Carpenter 
and Buchanan, 2008), but they have a distinct profile of adverse effects. Fewer 
extrapyramidal adverse effects are traded for more metabolic adverse effects including weight 
gain, hyperglycemia and dyslipidemia (De Hert et al., 2012a; De Hert et al., 2012b). The risk 
of such metabolic abnormalities appears to vary for different SGA, and to lower this risk has 
been an important goal in the development of more recently approved substances such as 
aripiprazole, ziprasidone and lurasidone (American Diabetes et al., 2004; Leucht et al., 2009). 
Nevertheless, current drug labels as well as international guidelines recommend that the 
metabolic profile should be monitored before and during treatment with SGA, particularly in 
patients with preexisting metabolic disorders and other cardiovascular risk factors (Mitchell et 
al., 2012). Therefore, studies on the frequency of metabolic disorders, their management, and 
the actual implementation of labeled recommendations in SGA users in routine clinical 
practice are an important contribution for the post-marketing evaluation of real-life risks and 
benefits of SGA (Mitchell et al., 2012; Verdoux et al., 2010). 
Furthermore, SGA can prolong the QTc interval with an associated increased risk of 
ventricular arrhythmia and sudden cardiac death (De Hert et al., 2012a; Weeke et al., 2014). 
The risk for cardiac and other adverse drug reactions may be enhanced by clinically relevant 
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drug interactions. Pharmacokinetic interactions may occur with inducers or inhibitors of the 
CYP450 enzyme system and may alter the plasma concentrations of SGA such as the 
CYP3A4 substrates clozapine and quetiapine. Pharmacodynamic interactions may also be 
problematic, e.g. when several QT-prolonging drugs are combined. Consequently a 
considerable number of drug combinations with SGA are labeled as formally contraindicated, 
and other potentially interacting combinations have labeled warnings requiring that the risk-
benefit ratio must be carefully assessed, and that close monitoring for adverse events must be 
performed. However, there is limited real-life data on the actual prevalence and clinical 
relevance of potentially interacting co-medication with SGA. 
 
The trend towards increased use of SGA may also be observed in tertiary care hospitals where 
patient characteristics, indications and usage patterns are different compared to psychiatric 
hospitals or outpatient settings. The current study therefore had three main aims that we 
wanted to evaluate in the real-life setting of a tertiary care hospital. First to explore 
prescribing patterns of SGA, second to analyze how metabolic complications of patients 
receiving SGA are monitored and managed, and third to analyze the prevalence, monitoring 




We conducted a retrospective observational study that analyzed SGA use and related 
population characteristics, metabolic profiles, concomitant pharmacotherapy and adverse 
events in a tertiary care hospital. The cantonal ethics committee, the hospital’s medical 
director and the hospital’s center for clinical research had approved the data extraction, the 
setup and analysis of the anonymized pharmacoepidemiological database and the access to 
original medical records for our research studies. 
 
  5 
Data Source 
For the current study we used comprehensive data for the time period from 1 January 2011 to 
31 December 2012 from our anonymized pharmacoepidemiological database containing 
information on demographics, laboratory results and electronic drug prescriptions for 
hospitalized patients of a tertiary care hospital. The hospital provides medical care to a 
population of about 1.5 million people and has approximately 1000 beds and 40 clinical 
specialty divisions.  The database builds on information extracted from the hospital’s 
electronic clinical information system featuring electronic drug prescription (computerized 
physician order entry, CPOE). The system records not only prescriptions but also a 
confirmation for each drug’s actual administration (and its time) to the patient. Our analyses 
included all prescriptions with documented administration from all hospitalized patients 
during the study period, except patients staying at intensive care units, where CPOE has not 
yet been introduced. We performed extensive reformatting, quality controls and matching of 
ATC codes to ensure identification of all administered drugs and their doses. In addition, we 
also compiled information on indication for SGA use, metabolic parameters, blood counts and 
ECG QTc-interval measurements for the population of the current study. 
 
Study population and design 
Selection of the study population and the overall study design are presented in Figure 1. All 
patients with at least one full calendar day of hospitalization and a documented administration 
of SGA were included into the study. The admission and the discharge day of each 
hospitalization were excluded from our analyses because drug administrations and events are 
not comprehensively recorded in the available data for those days. We included all SGA from 
our dataset that were defined as such by the US Federal Drug Administration (FDA, 2014a) 
and the German Psychiatrist's Association (DGPPN, 2006), i.e. amisulpride, aripiprazole, 
clozapine, olanzapine, paliperidone, quetiapine, risperidone and ziprasidone. Within the 
resulting study population we analyzed the following outcomes: 1. SGA usage patterns; 2. 
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metabolic parameters and their monitoring; 3. potential drug-drug interactions including 
associated adverse events and their monitoring. 
 
SGA usage patterns 
SGA use was descriptively analyzed regarding patient characteristics, primary diagnoses, 
indications and prescription frequencies. Indications for SGA use were determined according 
to all related information found in the electronic medical records and classified to one of the 
following 7 categories: 1. endogenous psychotic disorders (schizophrenia, schizoaffective 
disorders, other psychotic non-organic disorders); 2. exogenous psychotic disorders 
(substance induced behavior disorder or delirium, delirium in acute organic psychosis, 
dementia in chronic organic psychosis); 3. affective disorders (bipolar disorder with 
depressive or manic episode, depression); 4. personality disorder (borderline, emotional 
instability, other); 5. anxiety disorder and state of anxiety or excitation; 6. sleeping and eating 
disorders; 7. other indications (hallucination, agitation, somatogenic psychic disorder). 
 
Metabolic parameters and their monitoring 
Metabolic abnormalities were defined according to a published joint scientific statement of 
six international organizations (Alberti et al., 2009) and assessed for each hospitalization. 
Mean blood pressure was calculated from the first documented measurement on each patient 
day with SGA exposure for each hospitalization. Body mass index (BMI) was calculated from 
the first recorded measurement of height and weight during hospitalization or, if not available, 
derived from other information on nutritional status in the medical records. For metabolic 
laboratory values (blood glucose, HbA1c, and blood lipids) all measured values during 
hospitalization were recorded. We identified treatment with antidiabetic, antihypertensive and 
lipid-modifying drugs, and we also recorded treatment with glucocorticoids because these 
may increase blood glucose and therefore act as confounders. 
 
Potential drug interactions and associated adverse events 
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We identified potential drug-drug interactions of SGA with all contraindicated drugs that 
were administered on the same calendar day. For that purpose we first established a list of 
formally contraindicated drugs according to the manufacturers’ national drug labels for each 
SGA (www.swissmedicinfo.ch). For labeled contraindications that referred to specific drug 
characteristics (e.g. drugs known to cause QTc prolongation, agranulocytosis or drug 
metabolizing CYP450 enzyme inhibition) we established lists of drugs fulfilling those 
criteria. These were based on comprehensive available scientific information sources 
including specialized drug interaction software and websites (AZCERT, 2014; FDA, 2005, 
2014b; USA, 2014; www.mediq.ch, 2014). For drug combinations with SGA that were not 
formally contraindicated but require careful monitoring of the QTc-interval according to the 
manufacturers’ national drug labels, we established additional lists with the drugs’ 
Anatomical Therapeutic Chemical Classification System (ATC) codes. For all potentially 
interacting drugs that prolong QTc interval or inhibit CYP450 enzymes, we only included 
drugs that exhibit a strong or moderate effect according to at least one reference. We only 
analyzed hospitalizations where at least one strong CYP450 inhibitor or at least two moderate 
CYP450 inhibitors were co-administered at the same patient day. For every hospitalization for 
which we identified potential interactions with SGA, we validated whether any adverse events 
known to be associated with those interactions had actually occurred, and whether active 
monitoring for such events had been performed. We reviewed the original medical records for 
any events and clinical diagnoses that might represent an adverse drug reaction caused by the 
respective drug interactions. We checked whether ECG was monitored on days on which 
SGA were co-administered with contraindicated or potentially critically interacting drugs. 
Monitoring for QTc-prolongations was evaluated by reviewing all ECGs of all 
hospitalizations with QTc-prolonging drug combinations in the medical records. A QTc-
interval >450 ms in men and >460 ms in women is associated with increased cardiovascular 
mortality and defined the upper limit of normal by the American Heart Association, and this 
was accordingly categorized as "abnormal QTc" for the present study (Rautaharju et al., 2009; 
Schouten et al., 1991). A QTc-interval >500 ms significantly increases the risk of Torsades de 
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Pointes tachycardia and sudden cardiac death (Beach et al., 2013; FDA, 2005) and was 
defined as "long QTc" in our study. 
For contraindicated drug combinations with an increased risk of agranulocytosis that had been 
co-administered for at least three consecutive days, we reviewed results of all available blood 
counts. Neutropenia was defined as a neutrophil blood count <1.4 G/l, and agranulocytosis as 
a count <0.5 G/l. 
If an associated adverse event was documented, three investigators with special expertise in 
pharmacovigilance and formal causality assessment (SR, DN and CG) assessed the causal 
relationship of the adverse event with the interacting drug combination using internationally 
standardized WHO/CIOMS causality assessment criteria (Uppsala-Monitoring-Centre, 2012). 
 
Data analysis 
Data analysis is descriptive with presentation of results in tables as appropriate. Frequencies 
were calculated regarding individual patients, hospitalizations and patient days. Data 
management and analyses were done using STATA Version 13.1 (STATA Corporation, 
College Station, TX, USA). 
 
RESULTS 
The source population consisted of 53081 individual hospitalized patients contributing 82358 
hospitalizations and 495813 patient-days. After exclusion of patients without SGA use and 
less than at least one full calendar-day of hospitalization the resulting study population 
included 872 patients with 1136 hospitalizations and 9165 patient-days. In total, we analyzed 
the circumstances of 14214 single SGA administrations (Figure 1). 
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SGA usage patterns 
Characteristics of the study population are presented in Table 1. Females accounted for SGA 
use in 50.9% of the hospitalizations and 60.1% of the patient-days. Mean and median duration 
of hospitalization for all patients on SGA was 14 and 7 days, respectively. Quetiapine was the 
most frequently used SGA in the studied population (46.7% of all patient-days with SGA 
exposure), followed by olanzapine (27.9%) and risperidone (13.7%). The three most 
frequently co-administered drug groups with SGA were analgesics (ATC class N02, 8210 
patient days, 10.0% of all co-administered drugs), antithrombotic agents (ATC class B01, 
7485 patient days, 9.2%) and psychoanaleptics (ATC class N06, 6027 patient days, 7.1%). 
The small unit of psychiatry and psychotherapy (accounting for only 2.2% of all patient-days 
in the source population) expectedly had the highest prevalence of SGA use (on 23.8% of the 
patient-days in the unit) and accounted for 19.3% of all patient-days with SGA exposure in 
the hospital. The remaining 80.6% of SGA-use occurred in non-psychiatric units. In the 
neurology unit SGA were used on 6.5% of the patient-days, representing 14.5% of all SGA 
use at the hospital. Besides the psychiatry and neurology units, we found the highest 
prevalence of SGA exposure in the units of plastic surgery and infectious diseases (on 4.2% 
and 4.0%, respectively, of all patient days in these units). Due to their large absolute number 
of hospitalizations, trauma surgery and internal medicine were also major contributors to 
SGA use in the studied population (9.8% and 9.5%, respectively, of all patient-days with 
SGA exposure in the hospital). Indications for SGA prescriptions were identifiable in 899 
hospitalizations and are also presented in Table 1. Affective disorders (31.9%), endogenous 
psychotic disorders (24.9%) and exogenous psychotic disorders (19.6%) were the three most 
frequent documented indications for SGA. Most common primary diagnoses of patients 
receiving SGA during hospitalization according to their documented ICD-10 codes were 
cerebrovascular disorders (ICD codes I60-I69, 4.2%), behavioral disorders with somatic 
disorders and factors (ICD codes F50-F59, 3.9%) and other forms of heart disease (ICD codes 
I30-I52, 3.9%). During most hospitalizations only one SGA was administered per day, but in 
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5.7% of the analyzed hospitalizations two SGA were administered simultaneously on at least 
one patient-day, and in 0.2% three SGA. 
 
Metabolic parameters, their monitoring and treatment 
The monitoring of metabolic parameters in SGA users as well as the prevalence of metabolic 
disorders among those where monitoring was performed are presented in Table 2. Blood 
glucose and lipid profiles had not been determined in 24.3% (n=276) and 75.4% (n=856) of 
SGA users, respectively. In 58.3% of the cases in which any lab data on any metabolic status 
was available we found at least one metabolic abnormality. Furthermore, SGA users with 
prevalent metabolic disorders had no pharmacotherapy for those conditions in 63.4% of the 
hospitalizations with hyperglycemia, as well as in 70.8% and 37.1% with dyslipidemia and 
hypertension, respectively. Among all patients on SGA, 244 (28.0%) met the diagnostic 
criteria for metabolic syndrome as defined by a consensus group (Alberti et al., 2009). There 
were no apparent major differences in the prevalences of metabolic abnormalities between 
users of different SGA. 
 
Potential drug interactions and associated adverse events 
Prevalence of combined use of SGA with drugs that are formally contraindicated, as well as 
with drugs that are not formally contraindicated but have a labeled high risk of QTc-
prolongation in combination with SGA, are presented in Table 3. 
Co-administration of formally contraindicated drugs with SGA was present on 614 patient-
days emerging from 112 hospitalizations. Among those we identified 3 cases with clinically 
relevant adverse events that were related to the respective co-administrations with a 
“probable” causal relationship according to WHO/CIOMS causality criteria: one case with 
neutropenia and two with abnormal QTc. However, in 51 of the 112 hospitalizations, there 
was no monitoring of blood count or QTc interval, so the presence of related adverse events 
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cannot be excluded for those patients. Co-administrations of QT-prolonging combinations 
that were not formally contraindicated but potentially dangerous were identified in 176 
hospitalizations. Among those, ECG-monitoring for adverse events was performed in only 18 
patients (10.2%), and among those we identified 2 cases with abnormal QTc and a “probable” 




The current study analyzed SGA use and associated metabolic profiles and potential drug 
interactions including their outcomes in a real-life inpatient setting of a tertiary care hospital. 
We found that 1.6% of all hospitalized patients received SGA, about one third of SGA users 
were 65 years and older, more than 80% of SGA were prescribed to patients admitted for non-
psychiatric primary diagnoses, and that cerebrovascular disorders and heart disease ranked 
among the top three primary admission diagnoses. These features characterize SGA users in a 
tertiary care hospital as a high risk population for cardio- and cerebrovascular events and 
frequent polypharmacy, the latter predisposing to a high risk for drug interactions (Fritz et al., 
2012). Quetiapine and olanzapine accounted for the majority of SGA use, and both are well 
known to cause metabolic disorders and QT-prolongation. The predominant use of quetiapine 
is also in line with previous reports (Donohue et al., 2014; Greil et al., 2012), and quetiapine 
is subject to drug interactions with inducers and inhibitors of CYP3A4 drug metabolizing 
enzymes. Inducers and inhibitors of CYP450 enzymes are frequently used in tertiary care 
hospitals including e.g. several antiepileptic, antifungal and antibiotic drugs. Aripiprazole 
with its presumably lower risk for causing adverse metabolic effects was not as frequently 
used, but it is also subject to interactions via CYP2D6 and CYP3A4, and QT-prolongation is 
a well-known associated risk. Clozapine accounted for 10% of SGA use, and bone marrow 
suppression is a major concern in addition to its associated risk of interactions and QT-
prolongation. This risk is further elevated in combination with other drugs that may cause 
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neutropenia and agranulocytosis such as metamizole, methotrexate or azathioprine and 
requires regular blood count monitoring. Ziprasidone and lurasidone, which are comparable to 
aripiprazole in that they are also considered to have a low risk of metabolic disorders, were 
not (yet) marketed in Switzerland during the study period. 
Furthermore, documented indications suggest that off-label prescriptions account for a major 
part of SGA use in the studied setting, particularly for sleeping and eating disorders. This is in 
accordance with other studies in different populations and confirms the common practice of 
prescribing SGA beyond their labeled indication (Linden and Thiels, 2001; McKean and 
Monasterio, 2012). In some cases off-label use may constitute an avoidable risk and a formal 
and clinically relevant medication error. However, off-label use as well as the co-prescription 
of potentially interacting drugs does not necessarily have to be problematic, sometimes even 
for formally contraindicated drug combinations. In many instances it can be justified if 
possible risks are thoroughly weighed against benefits, and if there are no alternatives and no 
clear evidence regarding clinical relevance of risks. Nevertheless, such practice always 
implies at least an increased burden of responsibility for the prescribing physician and the 
hospital where it occurs. Therefore, in all those instances at least monitoring for adverse 
events should be taken seriously. From a broader perspective the growing number of persons 
exposed to SGA call for population studies assessing risks vs. benefits of SGA use, also for 
disorders other than psychosis and for unlabeled use (Verdoux et al., 2010). 
Our study provides a two-sided answer to these issues. On the one hand it is reassuring that 
we identified only five adverse events related to drug interactions with SGA use in our study 
population over a time of two calendar years, and none of them was irreversible. Given our 
thorough case-by-case evaluation we also consider it as unlikely that we missed serious 
adverse drug reactions caused by interactions with SGA during hospitalization. On the other 
hand, we found that among SGA users with according monitoring the prevalence of 
hypertension, hyperglycemia, dyslipidemia and BMI ≥30 kg/m² was 36.9, 22.6, 61.1 and 
23.1%, respectively, and that of those 37.1, 63.4 and 70.8%, respectively, had no 
pharmacotherapy for these conditions. Equally important we also found that a large 
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proportion of SGA users had insufficient monitoring regarding adverse metabolic effects and 
QT-prolongation. Furthermore, if problematic medication is continued, adverse events 
occurring after discharge may have remained undetected, particularly arrhythmia associated 
with QT-prolongation and long-term adverse effects of metabolic disorders (Weeke et al., 
2014). Indeed, in our function as a regional pharmacovigilance center we regularly receive 
reports of avoidable serious and sometimes fatal adverse drug reactions (particularly torsade 
de pointes tachycardia) associated with drug interactions with SGA, underlining their clinical 
relevance. Severe adverse effects of SGA and a need for improved monitoring in clinical 
practice are also documented in the literature. Girardin and colleagues reported fatal cases of 
arrhythmia associated with SGA in their well-designed prospective study (Girardin et al., 
2013). And a study in a Swiss psychiatric outpatient setting systematically screened SGA 
users for dyslipidemia and reported a prevalence of 21 to 27% (Choong et al., 2012). The low 
proportion of SGA users that are screened for metabolic abnormalities in the present study is 
also in line with results from a recent meta-analysis, which found that monitoring of 
metabolic risks in patients treated with antipsychotic medication is routinely performed in 
only 69.8 % (blood pressure), 44.3% (glucose), 59.9% (triglycerides) and 41.5% (cholesterol) 
(Mitchell et al., 2012). And in the CATIE landmark trial, 89% of patients with dyslipidemia 
and 45% of patients with diabetes were untreated (Manschreck and Boshes, 2007). 
For the interpretation of our findings, one has to consider some limitations imposed by the 
data source and study design. We followed patients during hospitalization, but for the time 
before admission and after discharge we were not able to collect comprehensive information 
on the duration of SGA use, metabolic profiles and adverse events. Therefore, frequencies of 
metabolic abnormalities must be seen as cross-sectional prevalence data, whereas no 
conclusions can be drawn on their incidence and causal relationship in relation to SGA use. 
Furthermore, some patients may have received SGA only for a short time, which may still be 
relevant for the risk of QT-prolongation, but less so regarding adverse metabolic outcomes. In 
addition prevalent metabolic abnormalities do not always equal an indication for 
pharmacological treatment. Nevertheless and regardless of these limitations, we must assume 
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that monitoring of the QT interval and/or metabolic parameters, management implications 
such as glucose and lipid lowering pharmacotherapy or switching to other SGA and avoiding 
interacting drug combinations would have been indicated in a considerable proportion of 
SGA users. 
 
From a pragmatic perspective one must realize that it is a challenging task to achieve changes 
in the prescribing and monitoring of SGA therapy with the aim to avoid critical interactions 
and adverse effects in clinical practice. However, the introduction of electronic medical 
records with electronic drug prescription provides new opportunities for efficient and 
effective clinical decision support. Today we already screen pharmacotherapy for potential 
medication errors in the electronic medical records at our institution as part of our proactive 
quality management efforts. We have also started the implementation of semi-automated 
screening algorithms for specific medication errors into our electronic prescribing system, 
followed by recommendations on patient management in case of clinical relevance. 
Implementation of such clinical decision support measures for SGA could help preventing 
associated adverse effects. Switching to SGA that are less likely to cause metabolic 
complications in patients with metabolic abnormalities has shown promising results and - if 
sufficient efficacy can be achieved - should be preferred over adding pharmacological 
treatment against the metabolic complications, which adds to the patients’ drug burden and 
may compromise their compliance (De Hert et al., 2012b; Mukundan et al., 2010; Tse et al., 
2014). 
 
In conclusion, our findings suggest that serious adverse effects of drug interactions with SGA 
are very rare, but also that a considerable proportion of patients with SGA exposure is neither 
adequately monitored nor managed, particularly concerning metabolic risks and QT-
prolongation. New opportunities through electronic medical records with highly specific 
electronic clinical decision support may play a key role for proactive safety management of 
antipsychotic and other pharmacotherapy in the future.  
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TABLE 1: Characteristics of the study population of second-generation 
antipsychotics (SGA) users in a tertiary care hospital 
Characteristics Hospitalizations n (%) 
Patient-days 
n (%) 
   
All analyzed SGA users 1136 (100) 9165 (100) 
   
 
Sex   
    Female 578 (50.9) 5506 (60.1) 
    Male 558 (49.1) 3659 (39.9) 
   
Age (years)   
    <18 8 (0.7) 131 (1.4) 
    18-44 280 (24.6) 3119 (34.0) 
    45-64 430 (37.9) 2787 (30.4) 
    65-84 357 (31.4) 2766 (30.2) 
    ≥85 61 (5.4) 362 (3.9) 
   
Use of different SGA1   
    Quetiapine 599 (52.7) 4276 (46.7) 
    Olanzapine  234 (20.6) 2543 (27.9) 
    Risperidone 170 (15.0) 1214 (13.7) 
    Clozapine 115 (10.1) 866 (9.4) 
    Aripiprazol 51 (4.5) 379 (4.1) 
    Amisulpride 22 (1.9) 102 (1.1) 
    Paliperidone 13 (1.1) 49 (0.6) 
    Ziprasidone 1 (0.1) 11 (0.1) 
   
Units with highest use of SGA2,3   
    Neurology 167 (14.7) 1325 (14.5) 
    Trauma surgery 134 (11.8) 900 (9.8) 
    Internal medicine 92 (8.1) 873 (9.5) 
    Neurochirurgy 66 (5.8) 455 (5.0) 
    Plastic surgery 66 (5.8) 457 (5.0) 
   
    Psychiatry-psychotherapy 37 (3.3) 1772 (19.3) 
   
Documented indications for SGA use4   
    Affective disorders 287 (31.9) 1897 (24.3) 
    Endogenous psychotic disorders 224 (24.9) 1439 (18.5) 
    Exogenous psychotic disorders 176 (19.6) 1278 (16.4) 
    Sleeping disorders and eating disorders 84 (9.3) 2110 (27.1) 
    Anxiety disorders 57 (6.3) 593 (7.6) 
    Other 48 (5.3) 361 (4.6) 
    Personality disorders 23 (2.6) 115 (1.5) 
   
    No indication documented5 237 (20.9) 1372 (15) 
       
 
Legend for Table 1 
1 Total of hospitalizations / patient-days exceeds number of analyzed hospitalizations / patient-days due 
to use of multiple SGA on some patient-days. Total of % therefore exceeds 100. 
2,3 % of hospitalizations: hospitalizations of all analyzed cases with use of SGA (1136 hospitalizations) 
    % of patient-days: prevalence of patient-days on these wards with use of any SGA in 2011 and 2012 
4 % of hospitalizations where indication was available (899 hospitalizations) 
5 % of hospitalizations with no indication of all hospitalizations (1136) / % of patient-days with no 
indication of all patient-days (9165)
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 Absolute and relative frequencies  
Total number of hospitalizations with SGA use  1136 (100%) 
  
Obesity  
 No weight, height or nutritional status documented 256 (22.6% of total) 
 BMI based on weight, height or additional data 880 (77.4% of total) 
        BMI ≥25 kg/m²     459 (52.1% of those with available BMI) 
        BMI ≥30 kg/m² (=“obesity”)     203 (23.1% of those with available BMI) 
  
Glycemic disorder  
 Blood glucose not measured 276 (24.3% of total) 
 Blood glucose values available 860 (75.7% of total) 
        Glycemic disorder1     194 (22.6% of those with glucose values) 
              Pharmacotherapy for diabetes         71 (36.6% of those with glycemic disorder) 
              Glucocorticoids co-administered         36 (18.6% of those with glycemic disorder) 
  
Lipid disorder  
 Blood lipids not measured 856 (75.4% of total) 
 Blood lipid values available 280 (24.6% of total) 
        Lipid disorder2     171 (61.1% of those with lipid values) 
             Pharmacotherapy for lipid disorder         50 (29.2% of those with lipid disorder) 
  
Hypertension  
 Blood pressure not measured 26 (2.3% of total) 
 Blood pressure values available 1110 (97.7% of total) 
     Hypertension3     410 (36.9% of those with blood pressure values) 
         Pharmacotherapy for hypertension         258 (62.9% of those with hypertension) 
 
Legend for Table 2 
Criteria for metabolic disorders were defined according to published consensus guidelines (Alberti et al., 
2009) 
1 Fasting glucose ≥5.6 mmol or spontaneous glucose ≥11.1 mmol/l or HbA1c > 5.9% (women) or >5.7% 
(men) 
2 Total cholesterol ≥5 mmol/l and/or HDL cholesterol ≤1mmol/l and/or triglycerides ≥1.7mmol/l 
3 Systolic blood pressure ≥130 or diastolic blood pressure ≥85 mmHg 
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TABLE 3: Drug interactions with SGA including their monitoring and associated adverse events 
 Overall use of 
involved SGA 
Use of SGA with 
contraindicated drug 














Hospitalizations (n) Case description 
Potentially interacting drug 
combinations 
      
a) Combinations with a labeled contraindication 
Clozapine and drugs that increase 
the risk of agranulocytosis 
 
114 866 68 349 15 Neutropenia under combined therapy of clozapine with metamizole 
(neutrophils 1.01 G/l, normal >1.4 G/l). Full recovery to normal values 
after stop of metamizole. 
Quetiapine and CYP3A4 inhibitors 
 
599 4276 30 182 25 Abnormal QTc (463 ms) under combined therapy of quetiapine with 
voriconazole. Therapy continued, no follow-up ECG. 
 
Amisulpride and drugs with high or 
moderate potential of QTc-
prolongation 
 
22 102 13 72 10 One case identified as part of internal quality management, but no 
documented consent from patient to publish details from original medical 
records for research purposes. 
Ziprasidone and drugs with high or 
moderate potential of QTc-
prolongation 
 
1 11 1 11 1 0 
b) Combinations with a labeled high risk of QT-prolongation without formal contraindication 
Clozapine and drugs with high and 
moderate potential of QTc-
prolongation 
 
115 866 58 388 51 Abnormal QTc (477 ms) under combined therapy of clozapine with 
quetiapine, sertindole, lithium, amitriptyline and ciprofloxacin. Therapy 
continued, no follow-up ECG. 
 
Risperidone and drugs with high 
and moderate potential of QTc-
prolongation 
 
170 1214 111 647 100 Abnormal QTc (487 ms) and symptomatic supraventricular extrasystoles 
under therapy with risperidone 5 hours after intravenous administration 
of ondansetrone. Normal QTc (435 ms) after stop of ondansetrone. 
 
Paliperidone and drugs with high 
and moderate potential of QTc-
13 49 7 31 7 0 
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prolongation 
 
 
 
